EUVIMEDEUVIMED entdecken
Crossref

T cell–mediated depletion of intratumoral regulatory T cells using a CCR8xCD3 T cell–engaging bispecific antibody (TCB) promotes antitumor immunity in preclinical mouse models

Baomei Wang iD, Isabel Ishizuka iD, Emel Esen iD, Ji Li iD, Cecilia Chiu iD, Yonglian Sun iD, Zhonghua Lin iD, Dhaya Seshasayee iD, Aija Kusi iD, Yu Zhong, Wendy Halpern iD, Adeyemi O Adedeji und 17 weitere

Science Translational Medicine · 2026

DOI: 10.1126/scitranslmed.aea7127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Baomei Wang und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Research Oncology, Genentech, South San Francisco, CA, USA. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Antibodies, Bispecific, Receptors, CCR8, Lymphocyte Depletion. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell–engaging bispecific antibodies (TCBs) have seen notable successes in hematologic malignancies, and emerging data demonstrate their potential for the treatment of solid tumors. Most oncology applications of TCBs have focused on targeting tumor cells via tumor-specific antigens; however, TCBs have been underutilized for strategic depletion of immunosuppressive cells in the TME. Regulatory T cells (T reg cells) play a crucial role in suppressing antitumor immune responses, making them an attractive target for immune-based therapies. T reg cells express several surface markers that can serve as potential targets for antibody-mediated depletion, including C-C chemokine receptor type 8 (CCR8), which is highly enriched on tumor-infiltrating T reg cells. Monoclonal antibody (mAb)–mediated T reg cell depletion relies on natural killer (NK) cells, which can be scarce in some solid tumors, whereas TCBs can broadly engage the T cell compartment by overwriting antigen specificity and redirecting potent T cell cytotoxicity against target cells. Here, we have developed a CCR8xCD3 TCB and show that it effectively depletes CCR8-expressing T reg cells in a T cell–mediated manner. CCR8xCD3 TCB led to the selective depletion of intratumoral T reg cells from human solid tumor samples in vitro and mediated inhibition of tumor growth in multiple syngeneic tumor models with variable levels of T cell infiltration alone or in combination with anti–PD-L1. In cynomolgus monkeys, CCR8xCD3 TCB was well tolerated without evidence of acute phase inflammation or cytokine release syndrome and led to effective and durable depletion of the CCR8-expressing subset of T reg cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryAntibodies, BispecificReceptors, CCR8Lymphocyte DepletionCD3 ComplexNeoplasmsAnimalsHumansCell Line, TumorDisease Models, AnimalMiceFemaleMacaca fascicularis

Substanzen

Antibodies, BispecificReceptors, CCR8CD3 Complex

Autor:innen und Institutionen

  • Department of Research Oncology, Genentech, South San Francisco, CA, USA.
  • Department of Translational Medicine, Genentech, South San Francisco, CA, USA.
  • Department of Antibody Engineering, Genentech, South San Francisco, CA, USA.
  • Department of Developmental Sciences Translational Safety, Genentech, South San Francisco, CA, USA.
  • Department of Developmental Sciences BioAnalytical Sciences, Genentech, South San Francisco, CA, USA.
  • Department of Translational Oncology, Genentech, South San Francisco, CA, USA.

ORCID-Profile: Baomei Wang, Isabel Ishizuka, Emel Esen, Ji Li, Cecilia Chiu, Yonglian Sun, Zhonghua Lin, Dhaya Seshasayee, Aija Kusi, Wendy Halpern, Zhaojun Yin, Giulia Protti, Soren Muller, Ran Li, Genee Lee, James T Koerber, Sascha Rutz, Teemu T Junttila

Zitieren

APA

Wang, B., Ishizuka, I., Esen, E., Li, J., Chiu, C., Sun, Y., Lin, Z., Seshasayee, D., Kusi, A., Zhong, Y., Halpern, W., Adedeji, A. O., Yu, L., Tran, P., Yin, Z., Yu, S. F., Del Rosario, G., Oei, Y., Yang, Y., …, & Junttila, T. T. (2026). T cell–mediated depletion of intratumoral regulatory T cells using a CCR8xCD3 T cell–engaging bispecific antibody (TCB) promotes antitumor immunity in preclinical mouse models. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aea7127

Vancouver

Wang B, Ishizuka I, Esen E, Li J, Chiu C, Sun Y, et al. T cell–mediated depletion of intratumoral regulatory T cells using a CCR8xCD3 T cell–engaging bispecific antibody (TCB) promotes antitumor immunity in preclinical mouse models. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aea7127

BibTeX
@article{Wang2026,
  author = {Wang, Baomei and Ishizuka, Isabel and Esen, Emel and Li, Ji and Chiu, Cecilia and Sun, Yonglian and Lin, Zhonghua and Seshasayee, Dhaya and Kusi, Aija and Zhong, Yu and Halpern, Wendy and Adedeji, Adeyemi O and Yu, Lanlan and Tran, Peter and Yin, Zhaojun and Yu, Shang-Fan and Del Rosario, Geoff and Oei, Yoko and Yang, Yagai and Schartner, Jill and Go, Mary Ann and Protti, Giulia and Muller, Soren and Wu, Cong and Li, Ran and Lee, Genee and Koerber, James T and Rutz, Sascha and Junttila, Teemu T},
  title = {T cell–mediated depletion of intratumoral regulatory T cells using a CCR8xCD3 T cell–engaging bispecific antibody (TCB) promotes antitumor immunity in preclinical mouse models},
  journal = {Science Translational Medicine},
  year = {2026},
  doi = {10.1126/scitranslmed.aea7127}
}
Kostenlos starten →